Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyne Therapeutics Inc (NQ: DYN ) 46.53 +1.04 (+2.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Dyne Therapeutics Inc < Previous 1 2 3 4 5 Next > Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity? August 21, 2024 Find out the significance of the Via Talk Markets Topics Stocks Exposures US Equities Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? August 13, 2024 A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to... Via Benzinga Topics Economy Exposures Interest Rates DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 August 12, 2024 DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 12, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... Via Benzinga Chart Of The Day: Dyne Therapeutics - Deeply Discounted July 10, 2024 Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United... Via Talk Markets Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease June 24, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress June 13, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday June 12, 2024 Via Benzinga Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React June 12, 2024 U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. Via Benzinga Topics Economy Exposures Interest Rates The 3 Most Undervalued Biotech Stocks to Buy in June 2024 June 04, 2024 https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate Via InvestorPlace Dyne Therapeutics to Present at Jefferies Global Healthcare Conference May 30, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares May 28, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session May 22, 2024 Via Benzinga Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock May 21, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Proposed Public Offering of Common Stock May 20, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Why Is Dyne Therapeutics Stock Soaring On Monday? May 20, 2024 Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle... Via Benzinga Tech Surge Boosts Nasdaq To Record Highs May 20, 2024 The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. Via Talk Markets Topics Stocks Exposures US Equities Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again May 20, 2024 Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. Via Investor's Business Daily Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday May 20, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday May 20, 2024 Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday! Via InvestorPlace Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints May 20, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET May 19, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 May 02, 2024 DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 02, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer March 27, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium March 27, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. Via Benzinga Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday March 25, 2024 U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Dyne Therapeutics Announces CEO Transition March 25, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.